肠促胰素在血糖稳态调节和2型糖尿病治疗中的作用

被引：29

作者：

NING Guang

机构：

[1] 上海交通大学附属瑞金医院内分泌代谢病科,上海市内分泌代谢病研究所,上海市内分泌代谢病临床医学中心

来源：

中华内分泌代谢杂志 | 2010年 / 26卷 / 09期

关键词：

肠促胰素; 血糖稳态; 糖尿病,2型;

D O I：

暂无

中图分类号：

R587.1 [糖尿病];

学科分类号：

100201 [内科学];

摘要：

肠促胰素(incretin)是一类在食物营养物质刺激下,由肠道内分泌细胞合成分泌的激素,具有葡萄糖依赖性促胰岛素分泌的特性,可通过促进β细胞的胰岛素分泌、抑制α细胞不适当的胰升糖素分泌、延缓胃排空及抑制食欲等多个途径参与机体血糖稳态调节.同时,肠促胰素还可促进β细胞增殖、抑制β细胞凋亡,增加胰岛素合成、改善β细胞功能,从而延缓甚至逆转2型糖尿病病程的进展.以肠促胰素为基础的治疗方案,包括胰升糖素样肽-1(GLP-1)类似物和二肽基肽酶-4(DPP-4)抑制剂将为2型糖尿病的治疗开辟一条新的途径。

引用

收藏

相关论文

共 13 条

[1]

Efficacy and safety of incretin-based therapies: Clinical trial data.[J].John White.Journal of the American Pharmacists Association.2009, 5

[2]

Incretin-based therapies in type 2 diabetes mellitus [J].

Chia, Chee W. ;

Egan, Josephine M. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :3703-3716

[3]

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study [J].

Moretto, Thomas J. ;

Milton, Denai R. ;

Ridge, Terry D. ;

MacConell, Leigh A. ;

Okerson, Ted ;

Wolka, Anne M. ;

Brodows, Robert G. .

CLINICAL THERAPEUTICS, 2008, 30 (08) :1448-1460

[4]

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance [J].

Rosenstock, Julio ;

Holst, Jens J. ;

Foley, James E. ;

Deacon, Carolyn F. ;

Rendell, Marc ;

Rochotte, Erika ;

Landin-Olsson, Mona ;

Baron, Michelle A. .

DIABETES CARE, 2008, 31 (01) :30-35

[5]

Update: vildagliptin for the treatment of Type 2 diabetes [J].

Garber, Alan J. ;

Sharma, Morali D. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (01) :105-113

[6]

Biology of incretins: GLP-1 and GIP [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

GASTROENTEROLOGY, 2007, 132 (06) :2131-2157

[7]

Mechanisms of action of glucagon-like peptide 1 in the pancreas [J].

Doyle, Maire E. ;

Egan, Josephine M. .

PHARMACOLOGY & THERAPEUTICS, 2007, 113 (03) :546-593

[8]

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[9]

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity [J].

Buteau, J ;

El-Assaad, W ;

Rhodes, CJ ;

Rosenberg, L ;

Joly, E ;

Prentki, M .

DIABETOLOGIA, 2004, 47 (05) :806-815

[10]

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study [J].

Zander, M ;

Madsbad, S ;

Madsen, JL ;

Holst, JJ .

LANCET, 2002, 359 (9309) :824-830